Key result
Weight loss drugs show divergent blood pressure effects, with some lowering while others raise BP.
Why the study?
The relationship between weight loss and hypertension and the effects of newly approved anti-obesity drugs on hypertension require further discussion and clarification.
Do weight loss interventions and anti-obesity drugs reduce blood pressure in overweight and obese patients?
Do weight loss interventions and anti-obesity drugs reduce blood pressure in overweight and obese patients?
Reduction in body weight with pharmacological treatment is not always associated with a reduction in obesity-induced hypertension, as some anti-obesity drugs may increase blood pressure.
Supports lifestyle weight loss for BP reduction; leaves open incremental value of new anti-obesity drugs in practice.
BACKGROUND: New insights on the relationship between weight loss and hypertension and the role of the newly approved anti-obesity drugs on hypertension will be discussed Methods: Weight loss is a major factor to reduce blood pressure when a patient with excess weight is advised from the health care provider to change his lifestyle. A healthy lifestyle with reduction in body weight, reduction in caloric intake, increased fruit and vegetables consumption and reduced salt intake concomitant with an increase in physical exercise can reduce body weight and hypertension in overweight and obese patients, but not all obese are able to reduce their blood pressure and lose weight without treatment and special dietary care. Moreover, most obese people lose weight for a small period and then they regain all the weight that they have lost or even worse, they increase their weight more than before starting a diet. Newly-approved weight loss drugs have variable actions on high blood pressure. Liraglutide and phentermine/topiramate seem to reduce hypertension, while after the bupropion/naltrexone or lorcaserin use trials reported a rise in blood pressure. CONCLUSION: Reduction in body weight with treatment is not always associated with reduction in obesity induced hypertension. Weight loss treatments that exhibit sympathomimetic or adrenergic actions should be used with care and for short periods of time.
No takes yet. Share an insight, caveat, or question.
Antza et al. (2017) conducted a review in Obesity-induced hypertension. Anti-obesity drugs was evaluated. Newly-approved weight loss drugs have variable actions on blood pressure, with liraglutide and phentermine/topiramate reducing it, while bupropion/naltrexone or lorcaserin may raise it.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: